

RIVAROXABAN 2.5mg tablets (Xarelto® ▼) for the prevention of atherothrombotic events

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of RIVAROXABAN 2.5mg tablets (Xarelto® ▼) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events – in combination with aspirin

GREY

Rivaroxaban has been granted a license extension and is now indicated, in combination with aspirin, for the prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic events.

- > This recommendation will be reviewed when the NICE TA is published. This is expected to be in August 2019.

References

1. Bayer plc. Summary of Product Characteristics - Xarelto 2.5mg tablets; August 2018. Accessed 15 November 2018 at: <https://www.medicines.org.uk/emc/product/3410/smpc>

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.